The Guardian: Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative
“An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. … The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit organization, is working with the Egyptian drugmaker Pharco Pharmaceuticals to bring a combination treatment of two hepatitis C tablets, ravidasvir ­(a new drug)­ and sofosbuvir, to countries that cannot afford to pay the high prices charged by U.S. companies Gilead and AbbVie…” (Kollewe, 4/12).